Pegozafermin Improves Fibrosis in NASH in Phase 2b Study ...Middle East

Medscape - News
In the phase 2b ENLIVEN trial, the investigational drug pegozafermin met both primary endpoints at 24 weeks and led to improvements in fibrosis, paving the way for phase 3 development. Medscape Medical News

Hence then, the article about pegozafermin improves fibrosis in nash in phase 2b study was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Pegozafermin Improves Fibrosis in NASH in Phase 2b Study )

Apple Storegoogle play

Last updated :

Also on site :